Propanc Biopharma, Inc.

Latest News

Mar 31, 2020

Propanc Biopharma Enters Into a $3 Million Financing with Institutional Investor

Company Plans to Undertake GMP Manufacture of PRP for a First-In-Human (FIH) Study in Advanced Cancer Patients MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the…

View All Press Releases

Mar 16, 2020

Propanc Biopharma’s Scientific Advisory Board Member Promoted to Professorship Position at Jaén University, Spain

Jan 21, 2020

Propanc Biopharma Receives Advance Overseas Finding from Innovation and Science Australia

Nov 18, 2019

Propanc Biopharma Advances POP1 Drug Discovery Program
Latest Publication Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting View All Publications
Antitumour efficacy of chymotrypsinogen and trypsinogen
In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation
A formulation of pancreatic pro-enzymes provides potent anti-tumour efficacy: a pilot study focused on pancreatic and ovarian cancer